Abstract
Cholinesterase inhibitors find application in the combat and care of several diseases, especially AD. Jellyfish venoms are the most promising sources of potent cholinesterase inhibitors. Therefore, it is of interest to study cholinesterases inhibiting compounds from the Cassiopea andromeda venom. We report bioactive compounds using the GC-MC method followed by molecular modeling and docking data analysis. The GC-MS analysis of the crude venom led to the identification of seven bioactive compounds (C1-C7), comprising the steroidal alkaloids, phenolic and carotenoid derivatives. The venom exhibited inhibitory activities against the cholinesterase enzymes. The compound C2, a Dioxolane steroid, displayed the strongest inhibition on both AChE and BChE activities for further consideration.
Highlights
Alzheimer’s disease (AD) is a neurodegenerative disease and the most cause of dementia [1]
AD is characterized by an insidious decrease or loss in memory, personality alteration, and decline of cognitive and non-cognitive functions, which thoroughly leads to disabling of the patient [2]
The catalytic site of the enzyme is positioned at this gorge known as the catalytic triad, which is consisted of His447, Glu334, and Ser203
Summary
Studies on the cholinesterases inhibiting compounds from the Cassiopea andromeda venom. Submitted on July 15, 2020; Revision August 5, 2020; Accepted August 6, 2020; Published September 30, 2020. The authors are responsible for the content of this article. The Editorial and the publisher has taken reasonable steps to check the content of the article with reference to publishing ethics with adequate peer reviews deposited at PUBLONS. Declaration on Publication Ethics: The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors declare that they are not withholding any information that is misleading to the publisher in regard to this article
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.